Stryker Co. (NYSE:SYK) Shares Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC boosted its position in Stryker Co. (NYSE:SYK - Free Report) by 14.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,579 shares of the medical technology company's stock after buying an additional 8,070 shares during the period. Sanctuary Advisors LLC's holdings in Stryker were worth $25,238,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Centennial Bank AR grew its position in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after buying an additional 48 shares during the period. Darwin Wealth Management LLC purchased a new position in Stryker in the third quarter valued at about $36,000. HBW Advisory Services LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at approximately $42,000. Finally, Hara Capital LLC purchased a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SYK has been the topic of a number of research analyst reports. UBS Group boosted their target price on Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Royal Bank of Canada restated an "outperform" rating and set a $425.00 target price (up from $400.00) on shares of Stryker in a report on Wednesday. Needham & Company LLC upped their price target on shares of Stryker from $409.00 to $442.00 and gave the company a "buy" rating in a report on Thursday. JPMorgan Chase & Co. increased their price target on shares of Stryker from $375.00 to $420.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Finally, Truist Financial lifted their price objective on Stryker from $370.00 to $380.00 and gave the stock a "hold" rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $404.35.

Stryker Trading Down 0.3 %

Shares of SYK stock traded down $1.07 during mid-day trading on Friday, reaching $373.99. The company's stock had a trading volume of 267,491 shares, compared to its average volume of 1,255,888. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $142.57 billion, a PE ratio of 40.19, a price-to-earnings-growth ratio of 2.84 and a beta of 0.94. The company's 50 day simple moving average is $372.88 and its 200-day simple moving average is $354.65. Stryker Co. has a 12-month low of $285.79 and a 12-month high of $398.20.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analysts' expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share. On average, research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. This is a positive change from Stryker's previous quarterly dividend of $0.80. Stryker's dividend payout ratio (DPR) is currently 34.30%.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares of the company's stock, valued at $3,685,213.16. This trade represents a 42.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.